Joakim Nyberg

Uppsala, C, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Objective First, Method Second: Why the Estimand Definition Comes First in Pharmacometric Covariate Modeling.

Objective First, Method Second: Why the Estimand Definition Comes First in Pharmacometric Covariate Modeling.

Journal: CPT: pharmacometrics & systems pharmacology

Published: February 10, 2026

Conditional Versus Unconditional Covariate Effects in Pharmacometric Models: Implications for Interpretation, Communication, and Reporting.

Conditional Versus Unconditional Covariate Effects in Pharmacometric Models: Implications for Interpretation, Communication, and Reporting.

Journal: CPT: pharmacometrics & systems pharmacology

Published: August 21, 2025

The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models.

The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models.

Journal: Journal of pharmacokinetics and pharmacodynamics

Published: November 27, 2024

Efanesoctocog Alfa Population Pharmacokinetics and Repeated Time-To-Event Analysis of Bleeds in Adults, Adolescents, and Children with Severe Hemophilia A.

Efanesoctocog Alfa Population Pharmacokinetics and Repeated Time-To-Event Analysis of Bleeds in Adults, Adolescents, and Children with Severe Hemophilia A.

Journal: Journal of clinical pharmacology

Published: November 19, 2024

Probing Exotic Cross-Shell Interactions at N=28 with Single-Neutron Transfer on ^{47}K.

Probing Exotic Cross-Shell Interactions at N=28 with Single-Neutron Transfer on ^{47}K.

Journal: Physical review letters

Published: September 19, 2024

Full random effects models (FREM): A practical usage guide.

Full random effects models (FREM): A practical usage guide.

Journal: CPT: pharmacometrics & systems pharmacology

Published: April 04, 2024

Reflection on clinical and methodological issues in rare disease clinical trials.

Reflection on clinical and methodological issues in rare disease clinical trials.

Journal: Orphanet journal of rare diseases

Published: February 13, 2024

Subcutaneous Marzeptacog Alfa (Activated) for On-Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors.

Subcutaneous Marzeptacog Alfa (Activated) for On-Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors.

Journal: Clinical pharmacology and therapeutics

Published: October 14, 2023

Using forest plots to interpret covariate effects in pharmacometric models.

Using forest plots to interpret covariate effects in pharmacometric models.

Journal: CPT: pharmacometrics & systems pharmacology

Published: October 13, 2023

Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials.

Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials.

Journal: Orphanet journal of rare diseases

Published: August 07, 2023

High-Precision Spectroscopy of ^{20}O Benchmarking Ab Initio Calculations in Light Nuclei.

High-Precision Spectroscopy of ^{20}O Benchmarking Ab Initio Calculations in Light Nuclei.

Journal: Physical review letters

Published: May 22, 2023

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin.

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin.

Journal: Pharmaceutics

Published: June 03, 2022

Showing 1-12 of 41

Last Updated: 09/26/2026